Skip to main content
TipRanks
Go Ultimate75% OFF

PanGenomic Health, Inc. Class A (NARA) AI Stock Analysis

33 Followers
TSE:NARA

PanGenomic Health, Inc. Class A

(CNQX:NARA)

Select Model
Rating:38Underperform
Price Target:CAD 0.28â–¼(-6.00% Downside)
Action:downgraded
Date:11/05/26

The score is driven primarily by severe financial weakness, reinforced by bearish trend signals and an unfavorable loss-based valuation profile. The weighted result is 38.15, rounded to 38.

Positive Factors
Moderate absolute debtDebt remains moderate in absolute dollar terms and has not been consistently high across every year. This provides some balance-sheet support relative to a more heavily indebted structure, although negative equity still limits financial flexibility and makes external funding important.
Negative Factors
Pre-revenue businessThe absence of reported revenue means the business has not yet demonstrated commercial traction or a functioning sales engine. Consistently negative gross profit further indicates that the core offering is not currently covering direct costs, leaving future viability dependent on achieving meaningful sales.

PanGenomic Health, Inc. Class A (NARA) vs. iShares MSCI Canada ETF (EWC)

-100%-75%-50%-25%0%25%50%TSE:NARA-66.67%EWC+21.04%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CAD 4.21M
Dividend Yield
―
Average Volume (3M)
15.44K
Price to Earnings (P/E)
-1.4
Beta (1Y)
-0.00
Revenue Growth
―
EPS Growth
43.30%
Country
Canada
Employees
0
Sector
Healthcare
Sector Strength
51
Industry
Medical - Healthcare Information Services

PanGenomic Health, Inc. Class A Business Overview & Revenue Model

Company Description

Pangenomic Health Inc. is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments to support mental health. The company's mobile app, the Nara App, provid...

PanGenomic Health, Inc. Class A Financial Statement Overview

Summary

Persistent pre-revenue losses, deeply negative equity, a very small asset base, and sustained cash burn indicate severe financial risk despite modest improvement from the weakest historical periods.

Income Statement

8Very Negative

Balance Sheet

6Very Negative

Cash Flow

7Very Negative
Financial statement breakdown
BreakdownTTMMar 2026Jun 2025Jun 2024Mar 2023Dec 2021
Income Statement
Total Revenue000000
Gross Profit-629-628―-681.43K-11.11K-2,127
EBITDA-4.23M-3.42M7,410-2.71M-3.57M-847.50K
Net Income-4.25M-3.43M-3,803-2.97M-20.35M-2.65M
Balance Sheet
Total Assets157.72K160.91K39.16K71.48K504.14K2.58M
Cash, Cash Equivalents and Short-Term Investments7,71738.77K1,30712.56K88.53K1.35M
Total Debt715.34K212.87K0964.75K101.77K0
Total Liabilities2.91M2.35M2.44M2.22M719.25K334.45K
Stockholders Equity-2.75M-2.19M-2.41M-2.14M-215.11K2.24M
Cash Flow
Free Cash Flow-2.21M-1.88M-58.25K-1.57M-2.79M-1.07M
Operating Cash Flow-2.21M-1.88M-58.25K-1.57M-2.78M-1.06M
Investing Cash Flow000-3,142-52.13K-604.91K
Financing Cash Flow2.21M1.92M47.00K1.50M1.57M2.97M

PanGenomic Health, Inc. Class A Technical Analysis

Technical Analysis SentimentPositive
Last Price0.30

Price Trends

50DMA0.24Positive
100DMA0.28Positive
200DMA0.35Negative

Market Momentum

MACD0.02Negative
RSI74.76Negative
STOCH100.00Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:NARA, the sentiment is Positive. The current price of 0.30 is above the 20-day moving average (MA) of 0.22, above the 50-day MA of 0.24, and below the 200-day MA of 0.35, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 74.76 is Negative, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:NARA.

PanGenomic Health, Inc. Class A Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TSE:NARA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:NDATTSE:NDAT45NeutralCAD 413.27K-16.67-49.83%――0.00%
TSE:ADKTSE:ADK41NeutralCAD 39.74M-7.999999.00%―-36.92%13.03%
TSE:UDOCTSE:UDOC41NeutralCAD 4.32M-1.33355.56%―614.03%51.97%
TSE:DMEDTSE:DMED39UnderperformCAD 3.29M-1.61739.84%――-28.35%
TSE:NARATSE:NARA38UnderperformCAD 4.21M-1.45184.91%――43.30%
TSE:AIDRTSE:AIDR38UnderperformCAD 44.05M-1.62-444.52%―415.06%-54.80%

* Healthcare Sector Average

Performance Comparison

0%500%1000%TSE:NARATSE:ADKTSE:NDATTSE:AIDRTSE:UDOCTSE:DMEDDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TSE:NARA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TSE:NARAPanGenomic Health, Inc. Class A0.30-0.60-66.67%
TSE:ADKDiagnos Inc0.330.0517.86%
TSE:NDATnDatalyze Corp0.01-0.00-33.33%
TSE:AIDRRocket Doctor Ai Inc0.43-0.40-48.21%
TSE:UDOCUnidoc Health Corp.0.05-0.15-75.00%
TSE:DMEDDiagnaMed Holdings Corp.0.03-0.05-66.67%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026